市場調查報告書
商品編碼
1403564
自動細胞計數全球市場規模、佔有率、產業趨勢分析報告:按產品、應用、最終用途、地區分類的展望與預測,2023-2030年Global Automated Cell Counting Market Size, Share & Industry Trends Analysis Report By Product, By Application (Cell Line development, Blood Analysis, Stem Cell Research, and Others), By End-use, By Regional Outlook and Forecast, 2023 - 2030 |
自動細胞計數市場規模預計到2030年將達到 86 億美元,預測期內年複合成長率為 12.2%。
根據 KBV 基數矩陣中的分析,F. Hoffmann-La Roche Ltd. 是市場上的領導者。2021年12月,F. Hoffmann-La Roche Ltd. 宣布推出三款用於乳癌影像分析的全新自動化數位病理演算法:uPath Ki-67(30-9)、uPath PR(1E2)和uPath ER(SP1 )。該演算法透過在病理學家評估之前自動預先計算玻片影像來促進整個玻片分析工作流程,這有助於病理學家量化乳癌標記。 Thermo Fisher Scientific、Abbott Laboratories 和 Danaher Corporation 等公司是該市場的主要創新者。
COVID-19 影響分析
在大流行期間,研究工作和資源主要用於了解 SARS-CoV-2 病毒、開發診斷測試和開發疫苗。研究重點的這種暫時轉變導致一些非新冠病毒相關研究領域的放緩,例如其他領域的自動細胞計數應用。這場流行病擾亂了全球供應鏈,影響了機械細胞計數設備和相關耗材的生產、分銷和可用性。製造延誤、出貨限制和物流挑戰暫時影響了市場成長。因此,COVID-19大流行對市場產生了溫和的影響。
市場成長要素
增加政府研發支出
增加政府對細胞研究的資助對於推進細胞生物學、再生醫學和相關領域的科學發現、創新和治療方法開發非常重要。增加的資金將使科學家更了解不同細胞類型的細胞機制、訊號途徑和行為。這些基礎知識為開發慢性病的標靶治療和介入措施提供了基礎。探索幹細胞在再生醫學、組織工程和疾病建模中的潛力為新的治療方法和器官再生打開了大門。因此,增加政府對研發的資助推動市場成長。
對細胞食品的需求不斷成長
細胞農業領域的不斷擴大,包括以細胞為基礎的牲畜、乳製品、雞蛋和其他產品的生產,為自動細胞計數設備帶來了新的應用。細胞生長和培養是製造過程的重要組成部分,需要密切監控。為食品生物製造設施開發符合良好生產規範(GMP)的自動計數解決方案的公司可以在這一利基市場中獲得價值。投資細胞農業公司並與之合作可以提供長期擴張機會。因此,細胞食品的上升趨勢推動市場成長。
市場抑制因素
需要專門的操作人員和培訓
先進的自動化細胞計數器需要熟練的員工和技術知識才能有效地操作和維護。許多實驗室由於預算和資源限制而被迫提供專門培訓。一個限制因素是缺乏合格的人力資源來充分發揮系統的潛力。護理學校和醫學院等醫療保健教育計畫能力不足,限制了進入該領域的合格專業人員的數量。因此,缺乏訓練有素的熟練勞動力阻礙了市場的成長。
產品展望
依產品分類,市場分為電器和消耗品/配件。2022年,消耗品和配件領域在市場中佔有最高的收益佔有率。隨著流式細胞儀、基於影像的細胞計數器和血液分析儀等自動細胞計數設備的採用不斷增加,對與這些設備相關的耗材和配件的需求也在增加。該市場對耗材和配件的需求不斷成長,與細胞分析技術的不斷擴大的應用以及標準化和品管的需要密切相關。
設備展望
設備區隔細分為流式細胞儀、基於影像的細胞計數器和電電阻計數器。2022年,流式細胞儀細分市場在市場中獲得了顯著的收益佔有率。這些儀器提供細胞的高通量和多參數分析,使研究人員、臨床醫生和製藥公司能夠更深入地了解細胞功能、疾病機制和治療開發。技術的進步、應用的擴展以及對精確和全面的細胞分析的需求不斷成長,導致對流式細胞儀的需求不斷成長。
應用前景
依應用分類,市場分為血液分析、幹細胞研究、細胞株開發等。2022年,血液分析領域在市場中獲得了顯著的收益佔有率。血液分析是臨床診斷的基礎。由於對準確及時診斷的需求、技術進步、對個人化醫療的關注,以及血液檢測在各種醫療保健環境、疾病管理、治療中的重要作用,推動了血液分析的需求不斷成長,已成為研究的基石。
最終用途展望
根據最終用途,市場分為製藥和生物技術公司、醫院和診斷實驗室、研究和學術機構等。製藥與生技公司細分市場2022年的收益佔有率最高。一些製藥和生物技術公司在市場上發揮重要作用,作為自動細胞計數設備的製造商,或是作為該技術用於研究、藥物開發和製造過程的用戶。
區域展望
從區域來看,對北美、歐洲、亞太地區和LAMEA的市場進行了分析。2022年,北美地區將佔據市場最大的收益佔有率佔有率。北美在市場上佔有重要地位。矽谷、波士頓和舊金山等叢集是許多生物技術公司和研究機構的所在地,這些公司和研究機構推動自動細胞計數技術的進步。政府對生命科學、生物技術和醫療保健研發的大力資助支持了細胞計數技術的進步。
The Global Automated Cell Counting Market size is expected to reach $8.6 billion by 2030, rising at a market growth of 12.2% CAGR during the forecast period.
Image-based cell counters offer high accuracy and precision in cell counting and analysis. Therefore, the Image-based Cell Counters segment captured $424.4 million revenue in the market in 2022. These systems use advanced imaging technology and algorithms to capture and analyze cell images, providing detailed information about cell morphology, viability, and concentration. As research methodologies become more advanced and diverse, the demand for accurate and efficient cell counting solutions, particularly those based on imaging technology, is expected to grow.
The major strategies followed by the market participants are Product Launches as the key developmental strategy to keep pace with the changing demands of end users. For instance, In September, 2022, Thermo Fisher Scientific, Inc. released the DynaSpin Single-Use Centrifuge system. The system is specifically meant for large-scale cell culture harvesting and aids the users in reducing overall production. Additionally, In October, 2021, Sysmex Corporation unveiled XN-30 Automated Haematology Analyzer for malaria detection. The XN-30 leverages a combination of specialized reagents, advanced algorithms, and violet laser to differentiate P. falciparum from non-falciparum species and find out the life cycle staging of the parasites detected.
Based on the Analysis presented in the KBV Cardinal matrix; F. Hoffmann-La Roche Ltd. are the forerunners in the market. In December, 2021, F. Hoffmann-La Roche Ltd announced the launch of three new automated digital pathology algorithms, uPath Ki-67 (30-9), uPath PR (1E2), and uPath ER (SP1) image analysis for breast cancer. The algorithms facilitate the whole slide analysis workflow with automated pre-computing of the slide image before pathologist assessment which aids the pathologists in quantification of the breast cancer markers. Companies such as Thermo Fisher Scientific, Inc., Abbott Laboratories and Danaher Corporation are some of the key innovators in the market.
COVID-19 Impact Analysis
During the pandemic, research efforts and resources were significantly redirected toward understanding the SARS-CoV-2 virus, developing diagnostic tests, and developing vaccines. This temporary shift in research priorities led to a slowdown in some regions of non-COVID-related research, including automated cell counting applications in other fields. The pandemic disrupted global supply chains, affecting the production, distribution, and availability of mechanical cell counting instruments and related consumables. Delays in manufacturing, shipping constraints, and logistical challenges temporarily impacted the market's growth. Therefore, the COVID-19 pandemic moderately impacted the market.
Market Growth Factors
Growing government expenditure for R&D
Increasing government funding for cell-based research is crucial in advancing scientific discoveries, technological innovations, and therapeutic developments in cell biology, regenerative medicine, and related areas. Increased funding allows scientists to delve deeper into understanding cellular mechanisms, signalling pathways, and the behaviour of various cell types. This fundamental knowledge forms the basis for developing targeted therapies and interventions for chronic diseases. Funding aids in exploring the potential of stem cells in regenerative medicine, tissue engineering, and disease modelling, paving the way for novel treatments and organ regeneration. Thus, the increasing government funding in research and development is driving the growth of the market.
Rising demand for cell-based food products
The growing domain of cellular agriculture, which encompasses the production of cell-based livestock, dairy, eggs, and other products, presents novel applications for automated cell counting instruments. Cell proliferation and culture constitute an integral component of the manufacturing process that necessitates meticulous oversight. Value can be captured in this niche by firms that develop good manufacturing practice (GMP) compliant automated counter solutions for food biomanufacturing facilities. Investments and partnerships with cellular agriculture firms may present opportunities for long-term expansion. Thus, the increasing trend of cell-based food is propelling the growth of the market.
Market Restraining Factors
Requirement for specialized operators and training
Proficient staff and technical knowledge are necessary to operate and maintain sophisticated automated cell counters effectively, particularly those that rely on images. Numerous laboratories hindered by budgetary and resource constraints must provide specialized training. The insufficiency of competent personnel capable of harnessing the complete potential of the systems constitutes a constraining element. Insufficient capacity in healthcare education programs, such as nursing schools and medical colleges, limits the number of qualified professionals entering the field. Hence, a scarcity of trained and skilful personnel is impeding the growth of the market.
Product Outlook
Based on product, the market is bifurcated into instruments and consumables & accessories. The consumables and accessories segment garnered the highest revenue share in the market in 2022. As the adoption of automated cell counting instruments like flow cytometers, image-based cell counters, and haematology analysers rises, so does the need for consumables and accessories associated with these instruments. The increasing demand for consumables and accessories in the market is closely linked to the expanding applications of cell analysis technologies and the need for standardization and quality control.
Instruments Outlook
The instruments segment is subdivided into flow cytometers, image-based cell counters, and electrical impedance coulter counters. In 2022, the flow cytometers segment procured a noteworthy revenue share in the market. These instruments provide high throughput and multiparametric analysis of cells, enabling researchers, clinicians, and pharmaceutical companies to gain deeper insights into cellular functions, disease mechanisms, and therapeutic developments. Technological advancements, expanding applications, and the increasing need for precise and comprehensive cell analysis contribute to the rising demand for flow cytometers.
Application Outlook
On the basis of application, the market is segmented into blood analysis, stem cell research, cell line development, and others. In 2022, the blood analysis segment attained a noteworthy revenue share in the market. Blood analysis is a fundamental aspect of clinical diagnostics. The increasing demand for blood analysis is driven by the need for accurate and timely diagnosis, technological advancements, a focus on personalized medicine, and the crucial role of blood testing in various healthcare settings, making it a cornerstone in disease management, treatment, and research.
End-Use Outlook
Based on the end-use, the market is categorized into pharmaceutical & biotechnology companies, hospitals & diagnostic laboratories, research & academic institutes, and others. The pharmaceutical & biotechnology companies segment witnessed the highest revenue share in the market in 2022. Several pharmaceutical and biotechnological companies play significant roles in the market, either as manufacturers of automated cell counting instruments or as users leveraging this technology for their research, drug development, and manufacturing processes.
Regional Outlook
Region-wise, the market is analysed across North America, Europe, Asia Pacific, and LAMEA. The North America region witnessed the maximum revenue share in the market in 2022. North America holds a significant position in the market. Regions like Silicon Valley and clusters in Boston and San Francisco are home to numerous biotech firms and research institutions driving technological advancements in automated cell counting. Robust government funding for research and development in life sciences, biotechnology, and healthcare supports advancements in cell counting technology.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Shanghai Ruiyu Biotechnology Co., Ltd. (Alit Biotech (Shanghai) Co., Ltd.), Thermo Fisher Scientific, Inc., Bio-Rad laboratories, Inc., F. Hoffmann-La Roche Ltd., Danaher Corporation, Olympus Corporation, Merck KGaA, Abbott Laboratories, Sysmex Corporation, and Agilent Technologies, Inc.
Recent Strategies Deployed in Automated Cell Counting Market
Product Launches and Product Expansions:
Sep-2022: Thermo Fisher Scientific, Inc. released the DynaSpin Single-Use Centrifuge system. The system is specifically meant for large-scale cell culture harvesting and aids the users in reducing overall production.
Dec-2021: F. Hoffmann-La Roche Ltd announced the launch of three new automated digital pathology algorithms, uPath Ki-67 (30-9), uPath PR (1E2), and uPath ER (SP1) image analysis for breast cancer. The algorithms facilitate the whole slide analysis workflow with automated pre-computing of the slide image before pathologist assessment which aids the pathologists in quantification of the breast cancer markers.
Oct-2021: Sysmex Corporation unveiled XN-30 Automated Hematology Analyzer for malaria detection. The XN-30 leverages a combination of specialized reagents, advanced algorithms, and violet laser to differentiate P. falciparum from non-falciparum species and find out the life cycle staging of the parasites detected.
Sep-2021: Merck KGaA introduced ProCellics Raman Analyzer, a cell culture analyzer. The system uses Bio4C PAT Raman software and delivers in-line and real-time cell culture monitoring.
Dec-2020: Merck KGaA announced the launch of the Scepter 3.0 handheld automated cell counter. The device delivers error-free cell counting by using a combination of analog and digital hardware for sensing, signal processing, data storage, and graphical display. Additionally, it contains a laser-drilled aperture in its cell-sensing zone.
Jan-2020: Olympus Corporation released the Provi CM20 monitoring system, a cell culture monitoring system. The system scans the cultures, and the number of cells and determines confluency on a periodical basis.
Partnerships, Collaborations & Agreements:
Oct-2023: F. Hoffmann-La Roche Ltd signed a partnership with Ibex Medical Analytics, an Israeli biotechnology company, to integrate its Navify Digital Pathology software platform with Ibex's AI-powered decision support tools. Through the partnership, Navify Digital Pathology platform pathologists would be able to securely access third-party AI-powered technology alongside Roche's growing menu of AI-based image analysis tools in an efficient clinical workflow.
Jun-2023: OGT, a subsidiary of Sysmex Corporation, announced a partnership with Applied Spectral Imaging (ASI), an advanced biomedical imaging solutions provider. Under the partnership, OGT would gain the marketing rights for ASI's proprietary cytogenetic imaging and analysis solutions. The partnership would enable clinical laboratories to strengthen their comprehensive genomic structural measurement capabilities.
Feb-2023: Thermo Fisher Scientific, Inc. came into partnership with Celltrio, a Cell Culture automation solutions provider, to develop a fully automated cell culture system for biotherapeutic applications. The solutions that would be developed in the course of the partnership would facilitate the users to deliver innovative therapies to patients by leveraging effective scale processing.
Aug-2020: Thermo Fisher Scientific, Inc. entered a partnership with FCS Express, a flow cytometry software offered by De Novo Software, to integrate its FCS Express software capability with its Invitrogen Attune NxT acoustic flow cytometer system. The combination of the two products would allow the customers to easily compare results across samples and produce publication-quality graphics at the time of instrument installation.
Mergers & Acquisition:
Feb-2021: Thermo Fisher Scientific, Inc. took over cell sorting technology assets from Propel Labs, a cell sorting solutions provider. The acquisition complements and strengthens Thermo Fisher's flow cytometry offering.
Trials and Approvals:
Aug-2023: Abbott Laboratories received approval from the US FDA for its Alinity h-series hematology system. The approval allows Abbott to strengthen its diagnostics business.
Market Segments covered in the Report:
By Product
By Application
By End-use
By Geography
Companies Profiled
Unique Offerings from KBV Research